| PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC M Del Re, R Marconcini, G Pasquini, E Rofi, C Vivaldi, F Bloise, ... British journal of cancer 118 (6), 820-824, 2018 | 252 | 2018 |
| Concise review: chronic myeloid leukemia: stem cell niche and response to pharmacologic treatment E Arrigoni, M Del Re, S Galimberti, G Restante, E Rofi, S Crucitta, ... Stem cells translational medicine 7 (3), 305-314, 2018 | 91 | 2018 |
| Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy M Del Re, S Crucitta, G Gianfilippo, A Passaro, I Petrini, G Restante, ... International journal of molecular sciences 20 (16), 3951, 2019 | 84 | 2019 |
| PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkers L Martí-Bonmatí, Á Alberich-Bayarri, R Ladenstein, I Blanquer, ... European radiology experimental 4, 1-11, 2020 | 63 | 2020 |
| Detection of ALK and KRAS mutations in circulating tumor DNA of patients with advanced ALK-positive NSCLC with disease progression during crizotinib treatment P Bordi, M Tiseo, E Rofi, I Petrini, G Restante, R Danesi, M Del Re Clinical lung cancer 18 (6), 692-697, 2017 | 61 | 2017 |
| Implications of KRAS mutations in acquired resistance to treatment in NSCLC M Del Re, E Rofi, G Restante, S Crucitta, E Arrigoni, S Fogli, M Di Maio, ... Oncotarget 9 (5), 6630, 2017 | 56 | 2017 |
| From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC P Bordi, M Del Re, R Minari, E Rofi, S Buti, G Restante, A Squadrilli, ... Lung Cancer 131, 78-85, 2019 | 48 | 2019 |
| Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide M Del Re, V Conteduca, S Crucitta, G Gurioli, C Casadei, G Restante, ... Prostate cancer and prostatic diseases 24 (2), 524-531, 2021 | 43 | 2021 |
| The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response M Del Re, P Bordi, E Rofi, G Restante, S Valleggi, R Minari, S Crucitta, ... British journal of cancer 119 (10), 1252-1258, 2018 | 41 | 2018 |
| Concise review: resistance to tyrosine kinase inhibitors in non-small cell lung cancer: the role of cancer stem cells M Del Re, E Arrigoni, G Restante, A Passaro, E Rofi, S Crucitta, ... Stem Cells 36 (5), 633-640, 2018 | 40 | 2018 |
| Artificial intelligence, radiomics and other horizons in body composition assessment S Attanasio, SM Forte, G Restante, M Gabelloni, G Guglielmi, E Neri Quantitative imaging in medicine and surgery 10 (8), 1650, 2020 | 38 | 2020 |
| Incidence of T790M in patients with NSCLC progressed to gefitinib, erlotinib, and afatinib: a study on circulating cell-free DNA M Del Re, I Petrini, F Mazzoni, S Valleggi, G Gianfilippo, D Pozzessere, ... Clinical lung cancer 21 (3), 232-237, 2020 | 36 | 2020 |
| Bridging gaps between images and data: a systematic update on imaging biobanks M Gabelloni, L Faggioni, R Borgheresi, G Restante, J Shortrede, ... European radiology, 1-14, 2022 | 22 | 2022 |
| Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors L Antonuzzo, M Del Re, V Barucca, F Spada, G Meoni, G Restante, ... Cancer Treatment Reviews 57, 28-35, 2017 | 22 | 2017 |
| Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase M Del Re, G Restante, A Di Paolo, S Crucitta, E Rofi, R Danesi Current Pharmaceutical Design 23 (14), 2028-2034, 2017 | 15 | 2017 |
| Patients with NSCLC may display a low ratio of p. T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment M Del Re, P Bordi, I Petrini, E Rofi, F Mazzoni, L Belluomini, E Vasile, ... Oncotarget 8 (49), 86056, 2017 | 14 | 2017 |
| Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment M Del Re, S Crucitta, G Restante, E Rofi, E Arrigoni, E Biasco, A Sbrana, ... Critical Reviews in Oncology/Hematology 125, 51-59, 2018 | 13 | 2018 |
| Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers E Rofi, M Del Re, E Arrigoni, M Rizzo, L Fontanelli, S Crucitta, ... Critical reviews in oncology/hematology 154, 102891, 2020 | 9 | 2020 |
| Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring F Pasqualetti, G Restante, A Gonnelli, E Rofi, A Molinari, S Crucitta, ... Neuro-oncology 21 (12), 1610-1611, 2019 | 9 | 2019 |
| Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers E Rofi, M Del Re, E Arrigoni, M Rizzo, L Fontanelli, S Crucitta, ... Critical Reviews in Oncology/Hematology 144, 102812, 2019 | 8 | 2019 |
